Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating ovarian cancer and related preparation thereof

A composition and chemotherapeutic drug technology, which is applied in the direction of drug combination, medical preparations containing active ingredients, antineoplastic drugs, etc., can solve the problem of poor curative effect, no reports of thymoquinone combined with dihydromyricetin in treating cancer, drug resistance Sexual problems are difficult to overcome and other problems, to achieve the effect of improving drug efficacy, protecting the liver, and reducing ROS levels

Active Publication Date: 2018-12-07
AFFILIATED HOSPITAL OF JIANGSU UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For most advanced ovarian cancers, platinum-based drugs are commonly used in clinical chemotherapy, but the problem of drug resistance has been difficult to overcome, resulting in poor efficacy
[0007] So far, there is no report on the treatment of cancer with thymequinone combined with dihydromyricetin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating ovarian cancer and related preparation thereof
  • Pharmaceutical composition for treating ovarian cancer and related preparation thereof
  • Pharmaceutical composition for treating ovarian cancer and related preparation thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1 Effects of Pharmaceutical Compositions and Monomers Thereon on the Proliferation of Ovarian Cancer Cell Lines

[0024] 1. In vitro culture of ovarian cancer cell lines

[0025] 1) Cell source

[0026] Human ovarian cancer cell lines SKOV3 and HO-8910 cells were purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences.

[0027] 2) Cell culture and passage

[0028] SKOV3 and HO-8910 cells used 1640 medium (Gibico). 10% fetal bovine serum (fetalbovineserum, FBS, Gibco) was added during cell culture. The above cell lines were all cultured in a 37°C, 5% CO2 incubator. When the cells grew to 80-90% of the bottom of the culture dish, they were digested and passaged with 0.25% trypsin+EDTA.

[0029] 2. Test method

[0030] Main experimental materials: Thymoquinone (Thymoquinone, TQ, Sigma) dissolved in methanol, prepared as a 10mM concentrated solution, at -20°C, diluted to 10, 20, 40, 80 and 100μM when used, ready to use. Dihydromyrictin (DHM, S...

Embodiment 2

[0051] Example 2 Induction Effect of Pharmaceutical Composition and Its Monomer on Ovarian Cancer Cell Apoptosis

[0052] Human ovarian cancer cell lines were purchased from Shanghai Institute of Cells, Chinese Academy of Sciences, and SKOV3 and HO-8910 cells used 1640 medium (Gibico). 10% fetal bovine serum (fetalbovineserum, FBS, Gibco) was added during cell culture. The above cell lines were all stored at 37°C, 5% CO 2 Culture in an incubator. When the cells grow to 80-90% of the bottom of the culture dish, they are digested with 0.25% trypsin+EDTA and passaged.

[0053] Test method: After the cells are digested into a cell suspension, they are spread in a 60mm culture dish at a suitable density, at 37°C, 5% CO 2 Incubate in the incubator for about 24 hours. When the cells grow to about 50% of the bottom of the culture dish, remove the original culture medium and add freshly prepared culture medium containing 20 μM TQ, 20 μM DHM and / or 5 mg / L cisplatin to continue the cul...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition containing thymoquinone and dihydromyricetin and application of the pharmaceutical composition to treatment of ovarian cancer, and belongs to thefield of medicines. The pharmaceutical composition contains the thymoquinone and the dihydromyricetin; and the mol ratio of the thymoquinone to the dihydromyricetin is 1 to (0.1 to 10).

Description

technical field [0001] The invention relates to a pharmaceutical composition containing thymequinone and dihydromyricetin and its application in the treatment of ovarian cancer, belonging to the field of medicine. Background technique [0002] Ovarian cancer is the second most common cancer in women. However, due to the lack of specific symptoms, early diagnosis of ovarian cancer is difficult, resulting in clinically diagnosed ovarian cancer is usually late and accompanied by extensive metastasis, and the prognosis is poor. Therefore, ovarian cancer has become the most lethal gynecological cancer. Currently, the 5-year survival rate of ovarian cancer worldwide is only 25%-30%. About 90% of ovarian cancers are derived from ovarian surface epithelium and fallopian tube epithelial cells, and 80% of ovarian epithelial cancers are serous papillary carcinomas. For most advanced ovarian cancers, platinum-based drugs are commonly used in clinical chemotherapy, but the problem of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/122A61K31/352A61P35/00
CPCA61K31/122A61K31/352A61P35/00A61K2300/00
Inventor 朱润芝殷润婷陈德玉马琳琳李小琴叶飞袁啸毛朝明刘义恩戴东方
Owner AFFILIATED HOSPITAL OF JIANGSU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com